• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Rectal administration of baclofen at the end of life
Spasticity can be a complicating symptom of a variety of neurological conditions such as multiple sclerosis, motor neuron disease, Creutzfeldt-Jakob disease, or post-stroke. Several pharmacological treatment options are available, including baclofen, tizanidine, gabapentin, botulinum toxin A and tetrahydrocannabinol/canabidiol (1, 2). However, treatment feasibility decreases as the end of life approaches, e.g. when patients are no longer able to tolerate oral medications, the onset of action would be too long, or the initiation of parenteral drug therapy (intravenous, intrathecal) is no longer indicated or appropriate.
Source: Journal of Pain and Symptom Management - August 7, 2018 Category: Palliative Care Authors: Charlotte Selge, Claudia Bausewein, Constanze Remi Source Type: research

Comparative study of therapeutic response to baclofen vs tolperisone in spasticity.
In this study we compared the efficacy and safety of baclofen vs tolperisone in spasticity. One hundred fifty patients with cerebral palsy or post stroke or spinal cord injury associated spasticity were enrolled in present study. Group I comprised of Seventy-five patients receiving baclofen and group II comprised of 75 patients receiving tolperisone. For efficacy measurement 4 evaluation methods were used, 1) Modified Ashworth Scale for muscle tone, 2) Medical research council scale for muscle strength and 3) Barthel Index for functional outcome 4) Coefficient of efficacy. In efficacy evaluation, both groups showed signifi...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - January 9, 2017 Category: Drugs & Pharmacology Authors: Agarwal S, Patel T, Shah N, Patel BM Tags: Biomed Pharmacother Source Type: research